免疫-PET检测了与他类药物同时使用的抗体药物强度
Emma L Brown1, Shayla Shmuel1, Komal Mandleywala2
1Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri.
概括
洛瓦斯塔丁在胃癌模型中增强了针对HER2的抗体-药物合物 (ADC) 的疗效. 这种组合疗法,包括trastuzumab emtansine (T-DM1),改善了瘤生长抑制,并允许单剂量ADC的使用.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 医疗成像医学成像
背景情况:
- 像T-DM1和T-DXd这样的HER2向抗体-药物结合体 (ADC) 对HER2阳性癌症至关重要.
- 洛瓦斯塔丁是一种他类药物,可以增加细胞表面的HER2表达,从而有可能改善ADC向.
研究的目的:
- 在胃癌模型中研究使用和不使用洛瓦斯塔丁的ADC治疗的疗效.
- 为了评估单剂量和多剂量ADC疗法与洛瓦斯塔丁结合使用.
主要方法:
- 利用NCIN87和来自患者的胃外移植模型.
- 用于免疫PET成像的注射Zr-或Cu-标记的特拉斯图祖马布.
- 使用单剂和多剂的洛瓦斯塔丁和没有洛瓦斯塔丁的T-DM1和T-DXd的疗效比较.
主要成果:
- 在单剂和多剂方案中,T-DM1与洛瓦斯塔丁抑制了瘤生长.
- 单剂量洛瓦斯塔丁与T-DM1或T-DXd结合,显著增强了瘤生长抑制.
- 免疫PET显示HER2信号下降,细胞分析显示组合疗法降低了HER2信号.
结论:
- 针对HER2的免疫PET可以预测瘤对ADC疗法的反应,并结合目标可用性调节器.
- 像洛瓦斯塔丁一样,他类药物在胃癌模型中增强了ADC的疗效,使单剂量ADC的使用成为可能.
相关概念视频
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
161
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Fundamental Principles of PET
161
01:29Positron Emission Tomography
4.3K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.3K